Business
miRagen Reports Fourth Quarter and Full Year 2019 Financial Results
Completed enrollment of 37 patients in the Phase 2 SOLAR trial of cobomarsen in CTCL; expects to report topline data in Q3 2020Completed initial planned
About this update from Viridian Therapeutics, Inc.
[{"type":"text","content":"Completed enrollment of 37 patients in the Phase 2 SOLAR trial of cobomarsen in CTCL; expects to report topline data in Q3 2020Completed initial planned enrollment of the Phase 1 trial of cobomarsen in ATLL patients; reported additional data in January 2020; expects to meet with the FDA in Q3 2020 to explore a potential expedited development path Entered into a $20.0 million stock purchase agreement in December 2019; $5.1 million funded to dateClosed $15.0 million equity offering in February 2020 extending cash runway into Q3 2021Reported $26.8 million in cash, cash equivalents, and short-term investments as of December 31, 2019Management to host conference call today at 4:30 p.m. ET BOULDER, Colo., March 11, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), today reported operating highlights and financial results for the quarter and full-year ended December 31, 2019 and provided an outlook for 2020.\n “In 2019, we announced a series of changes intended to streamline our focus and operations. As a result, we enter 2020 with the opportunity to deliver several important milestones. We started the year by announcing positive new data for cobomarsen in ATLL patients in January and completed a $15.0 million equity financing in February which we believe extends our cash runway into the third quarter of 2021,” stated miRagen President and Chief Executive Officer, William S. Marshall, Ph.D. “In the next few quarters, we look forward to meeting with FDA to discuss a potentially expedited development path for cobomarsen in ATLL, reporting topline data from the Phase 2 cobomarsen SOLAR trial in CTCL, and reporting additional preclinical data for MRG-229, our idiopathic pulmonary fibrosis (IPF) therapy product candidate. We believe this program provides us an exciting opportunity to deliver a potentially differentiated approach for the treatment of patients with IPF.” Summary of Program Highlights Cobomarsen: Cobomarsen is currently being evaluated for the potential treatment of patients with miR-155 elevated hematological malignancies, including Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia/Lymphoma (ATLL). Cutaneous T-Cell Lymphoma: In December 2019, the Company announced plans to stop the enrollment of new patients in the SOLAR trial and conduct an analysis of topline clinical response. This analysis will ...